Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

March 18, 2019

Some PC Patients Can Safely Receive Short but Intense Course of Radiation

News

Stereotactic body radiotherapy (SBRT), which delivers higher doses of radiation over a significantly shorter period of time, can be safely given to men with low- or intermediate-risk prostate cancer with ... Read more

March 13, 2019March 13, 2019

Trial To Test Lynparza-Zytiga Combo Recruiting Men with Metastatic Castration-resistant Prostate Cancer

News

A Phase 3 trial is recruiting men to test a combination of Lynparza (olaparib) and Zytiga (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Named PROpel ... Read more

March 7, 2019

Darolutamide Delays Metastasis in High-risk CRPC Patients, Phase 3 Trial Shows

News

Adding the androgen receptor inhibitor darolutamide to androgen deprivation therapy (ADT) extends by 22 months the time men with castration-resistant prostate cancer live without metastasis, without increasing the incidence of adverse events, results ... Read more

February 21, 2019

PSA Testing Cuts Deaths, Shows Value of Long-Term Screening

News

A blood test measuring the levels of PSA — a well-known marker of prostate cancer — cuts deaths from the disease by nearly 30%, the longest screening study on ... Read more

February 14, 2019

Xtandi Delays Disease Progression, Death in Metastatic Hormone-Sensitive PC Patients, Trial Shows

News

Adding the androgen receptor inhibitor Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression — assessed through radiological imaging — or death among metastatic hormone-sensitive prostate cancer patients, ... Read more

February 4, 2019

Erleada Improves Survival in Metastatic Castration-Sensitive Prostate Cancer, Phase 3 Trial Finds

News

Adding Janssen‘s androgen receptor inhibitor Erleada (apalutamide) to first-line androgen deprivation therapy (ADT) significantly extended survival and delayed disease progression or death in metastatic castration-sensitive prostate cancer patients included in a Phase ... Read more

January 17, 2019

Erleada Approved in Europe for Castration-resistant Prostate Cancer Patients at High Risk of Metastasis

News

The European Commission has approved the use of Erleada (apalutamide) for the treatment of men with castration-resistant prostate cancer at high risk of developing metastasis, announced Janssen Oncology, the therapy’s developer. The ... Read more

January 7, 2019

Phase 2 Trial Assessing CPI-1205, Plus Xtandi, Begins Dosing Metastatic CRPC Patients

News

Constellation Pharmaceuticals has begun patient dosing in the second part of a Phase 1b/2 trial testing its investigational inhibitor CPI-1205, in combination with Xtandi (enzalutamide), for the second-line treatment of ... Read more

January 3, 2019

Trial Studies Gold Nanoparticles as Way to Eliminate Localized Prostate Cancer

News

A new approach that uses light-activated gold nanoparticles is being tested in a small clinical trial as a way to eliminate prostate cancer in patients with localized tumors. The ... Read more

December 13, 2018

10-Year Survival of Young Low- and Intermediate-risk Prostate Cancer Patients Better with Radiation than Surgery

News

Radiation therapy approaches — including brachytherapy and external beam radiation therapy (EBRT) — lead to better 10-year survival rates than prostate surgery in young patients with low- and intermediate-risk ... Read more

Pin It on Pinterest